Login / Signup

Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics.

Angelo Gámez-PozoLucía Trilla-FuertesGuillermo Prado-VázquezCristina ChivaRocío López-VacasPaolo NanniJulia Berges-SoriaJonas GrossmannMariana Díaz-AlmirónEva CiruelosEduard SabidóEnrique EspinosaJuan Ángel Fresno Vara
Published in: PloS one (2017)
This study identified a protein combination signature that complements histopathological prognostic factors in TNBC treated with adjuvant chemotherapy. The protein signature can be used in paraffin-embedded samples, and after a prospective validation in independent series, it could be used as predictive clinical test in order to recommend participation in clinical trials or a more exhaustive follow-up.
Keyphrases
  • prognostic factors
  • clinical trial
  • protein protein
  • small molecule
  • mass spectrometry
  • physical activity
  • binding protein
  • high throughput
  • cancer therapy
  • drug delivery
  • open label
  • label free